Insulet Forecasts 28.6% Q4 Revenue Rise to $768.2M with $1.46 EPS
Insulet posted Q3 sales of $706.3 million, up 29.9% year-over-year and 3.9% above analysts’ estimates, and analysts forecast Q4 revenue of $768.2 million (28.6% growth) with adjusted EPS of $1.46. The stock has declined 14.6% over the past month and carries an average price target of $369.64.
1. Q3 Financial Results
Insulet reported Q3 revenue of $706.3 million, marking a 29.9% increase year-over-year and exceeding consensus estimates by 3.9%. This performance continued a two-year streak of revenue beats, averaging 5.3% above forecasts.
2. Q4 Projections
Analysts project Q4 revenue of $768.2 million, a 28.6% year-over-year increase compared with Q4 last year’s 17.2% growth, and adjusted earnings of $1.46 per share. Consensus estimates have remained stable over the past 30 days, reflecting confidence in the company’s growth trajectory.
3. Stock Performance and Peer Comparison
Insulet’s share price is down 14.6% over the last month, underperforming healthcare equipment peers, which fell an average of 3.7%. The stock trades below its average analyst target of $369.64, while peers ResMed and DexCom delivered 11% and 13.1% revenue growth in Q4, respectively.